Skip to content

Lantheus

US · LNTH #1847 by market cap Listed 2015
100.29 +0.11 +0.10%
Live - 5344 symbols - heartbeat 457s ago · 2026-10-08 09:59
Pre-market 100.00 -0.18%
After-hours 99.90 -0.28%
Overnight 100.98 +0.80%
Market cap
6.55B
P/B
4.99
EPS
3.41
Reader sentiment Are you bullish or bearish on LNTH?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 4.97 Cheap vs history 29th percentile
5-year average 6.53 · #53 of 70 in Drug Manufacturers - Specialty & Generic
P/E ratio 23.90 In line with history 61st percentile
5-year average 10.16 · forward 18.43 · #17 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 4.19 In line with history 43rd percentile
5-year average 4.76 · forward 4.26 · #55 of 80 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Lantheus (LNTH) 6.55B 23.99 4.99 0.00%
Takeda Pharmaceutical (TAK) 58.76B -55.74 1.23 3.25%
Teva Pharmaceutical Industries (TEVA) 45.28B 64.70 5.84 0.00%
Haleon (HLN) 40.15B 19.10 1.86 2.08%
Zoetis (ZTS) 29.69B 11.72 9.43 2.87%
United Therapeutics (UTHR) 23.14B 19.33 3.62 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value84.51 Economic moatNarrow UncertaintyHigh

Trading 15.7% above Morningstar's fair value estimate.

Fair value

Lantheus Holdings Inc receives a 2-star quantitative star rating, reflecting our opinion that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 19% premium over our quantitative fair value estimate of $84.51 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 20.1% falls in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

On a different note, the firm's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 6.0%, for example, sits in the top 40% globally. This suggests that it is generating substantial earnings relative to its share price, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-10-08 09:59:54 · For reference only, not investment advice and not tailored to your situation.